Stock data
Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. (LXEO) reported net income of -US$99.96M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$109.26M | -US$99.96M | — |
| 2024 | — | — | -US$105.77M | -US$98.33M | — |
| 2023 | — | — | -US$68.51M | -US$66.39M | — |
| 2022 | US$0.65M | — | -US$60.51M | -US$59.28M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$25.87M | — |
| 2026-03-31 | — | -US$20.20M | — |
| 2025-12-31 | — | -US$20.92M | — |
| 2025-09-30 | — | -US$20.28M | — |
| 2025-06-30 | — | -US$26.10M | — |
| 2025-03-31 | — | -US$32.66M | — |
| 2024-12-31 | — | -US$25.92M | — |
| 2024-09-30 | — | -US$29.49M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.